{
  "data": {
    "type": "predisposition_risk",
    "data": [
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TRISEQUENS_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.66,
        "risk_count": 9361,
        "predisposition_and_risk": 11,
        "risk_duration": 27017595,
        "predisposition_and_risk_duration": 19136,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MEBENDAZOLE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "MEBENDAZOLE",
        "rr": 1.62,
        "risk_count": 19035,
        "predisposition_and_risk": 22,
        "risk_duration": 26904286,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.KLIOGEST_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "KLIOGEST CD",
        "rr": 1.42,
        "risk_count": 19475,
        "predisposition_and_risk": 20,
        "risk_duration": 26454537,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.GOSERELIN",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "GOSERELIN",
        "rr": 1.33,
        "risk_count": 12122,
        "predisposition_and_risk": 20,
        "risk_duration": 22918906,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.CIMETIDINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "CIMETIDINE",
        "rr": 1.32,
        "risk_count": 12233,
        "predisposition_and_risk": 11,
        "risk_duration": 28117856,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.EUCALYPTUS_OIL",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "EUCALYPTUS OIL",
        "rr": 1.3,
        "risk_count": 9240,
        "predisposition_and_risk": 15,
        "risk_duration": 22780385,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.POVIDONE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "POVIDONE",
        "rr": 1.29,
        "risk_count": 17795,
        "predisposition_and_risk": 16,
        "risk_duration": 27477417,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMIPRAMINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "IMIPRAMINE",
        "rr": 1.29,
        "risk_count": 24039,
        "predisposition_and_risk": 22,
        "risk_duration": 26976757,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BLEPHAMIDE_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BLEPHAMIDE CD",
        "rr": 1.27,
        "risk_count": 12705,
        "predisposition_and_risk": 11,
        "risk_duration": 28015822,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DOXYLAMINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DOXYLAMINE",
        "rr": 1.27,
        "risk_count": 8224,
        "predisposition_and_risk": 13,
        "risk_duration": 22847493,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BRONCHOLATE_NEW_FORMULA_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BRONCHOLATE NEW FORMULA CD",
        "rr": 1.25,
        "risk_count": 36605,
        "predisposition_and_risk": 35,
        "risk_duration": 25055425,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.DURATEARS_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DURATEARS CD",
        "rr": 1.24,
        "risk_count": 12222,
        "predisposition_and_risk": 19,
        "risk_duration": 22671179,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ALPHOSYL_.22.222_IN_1.22.22_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ALPHOSYL \"\"2 IN 1\"\" CD",
        "rr": 1.22,
        "risk_count": 19735,
        "predisposition_and_risk": 17,
        "risk_duration": 27191923,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DIMENHYDRINATE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DIMENHYDRINATE",
        "rr": 1.19,
        "risk_count": 40666,
        "predisposition_and_risk": 37,
        "risk_duration": 24960261,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DURATEARS_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DURATEARS CD",
        "rr": 1.18,
        "risk_count": 33101,
        "predisposition_and_risk": 28,
        "risk_duration": 26681786,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MINOXIDIL",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "MINOXIDIL",
        "rr": 1.18,
        "risk_count": 14751,
        "predisposition_and_risk": 12,
        "risk_duration": 27723053,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CHLORPROMAZINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "CHLORPROMAZINE",
        "rr": 1.17,
        "risk_count": 13150,
        "predisposition_and_risk": 20,
        "risk_duration": 21895285,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROXYCARBAMIDE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "HYDROXYCARBAMIDE",
        "rr": 1.17,
        "risk_count": 22141,
        "predisposition_and_risk": 18,
        "risk_duration": 27509805,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ASCORBIC_ACID.2DPROPOLIS_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ASCORBIC ACID-PROPOLIS CD",
        "rr": 1.15,
        "risk_count": 8345,
        "predisposition_and_risk": 12,
        "risk_duration": 22845141,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MIGRALEVE_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "MIGRALEVE CD",
        "rr": 1.15,
        "risk_count": 13610,
        "predisposition_and_risk": 11,
        "risk_duration": 27293291,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.GLYCERIN.2DSORBITOL_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "GLYCERIN-SORBITOL CD",
        "rr": 1.14,
        "risk_count": 21451,
        "predisposition_and_risk": 17,
        "risk_duration": 27410375,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.METFORMIN_AND_LINAGLIPTIN_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "METFORMIN AND LINAGLIPTIN CD",
        "rr": 1.14,
        "risk_count": 22795,
        "predisposition_and_risk": 18,
        "risk_duration": 27546196,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.RADIAN_B_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "RADIAN B CD",
        "rr": 1.12,
        "risk_count": 14607,
        "predisposition_and_risk": 21,
        "risk_duration": 22252966,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.TIMOLOL.2D_BRINZOLAMIDE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.12,
        "risk_count": 13542,
        "predisposition_and_risk": 19,
        "risk_duration": 22704104,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BORIC_ACID",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BORIC ACID",
        "rr": 1.12,
        "risk_count": 8579,
        "predisposition_and_risk": 12,
        "risk_duration": 22776001,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.FLUOCINOLONE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "FLUOCINOLONE",
        "rr": 1.12,
        "risk_count": 16766,
        "predisposition_and_risk": 13,
        "risk_duration": 27730513,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.AMOROLFINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "AMOROLFINE",
        "rr": 1.11,
        "risk_count": 29723,
        "predisposition_and_risk": 24,
        "risk_duration": 26372971,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.EYE_CARE_WIPES",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "EYE CARE WIPES",
        "rr": 1.11,
        "risk_count": 29247,
        "predisposition_and_risk": 23,
        "risk_duration": 26913256,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.PROCTOZORIN_.2D_N_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "PROCTOZORIN - N CD",
        "rr": 1.1,
        "risk_count": 10745,
        "predisposition_and_risk": 15,
        "risk_duration": 22472214,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANKLE_BRACE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ANKLE BRACE",
        "rr": 1.09,
        "risk_count": 19573,
        "predisposition_and_risk": 28,
        "risk_duration": 21667459,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ISOCONAZOLE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ISOCONAZOLE",
        "rr": 1.09,
        "risk_count": 8817,
        "predisposition_and_risk": 12,
        "risk_duration": 22767921,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.SOY_ISOFLAVONES",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.08,
        "risk_count": 15351,
        "predisposition_and_risk": 12,
        "risk_duration": 26320416,
        "predisposition_and_risk_duration": 19136,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TICAGRELOR",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.08,
        "risk_count": 14824,
        "predisposition_and_risk": 11,
        "risk_duration": 27971378,
        "predisposition_and_risk_duration": 19136,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DEXPANTHENOL.2DSODIUM_HYALURONATE_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DEXPANTHENOL-SODIUM HYALURONATE CD",
        "rr": 1.08,
        "risk_count": 21360,
        "predisposition_and_risk": 16,
        "risk_duration": 27531156,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_ASPART",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "INSULIN ASPART",
        "rr": 1.08,
        "risk_count": 108469,
        "predisposition_and_risk": 149,
        "risk_duration": 14998217,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PENCICLOVIR",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "PENCICLOVIR",
        "rr": 1.07,
        "risk_count": 18649,
        "predisposition_and_risk": 14,
        "risk_duration": 27157107,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.TIMOLOL.2DTRAVOPROST_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.07,
        "risk_count": 16493,
        "predisposition_and_risk": 12,
        "risk_duration": 28222262,
        "predisposition_and_risk_duration": 19136,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ZINCOD_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.07,
        "risk_count": 11130,
        "predisposition_and_risk": 15,
        "risk_duration": 22669033,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.RAFATHRICIN_WITH_BENZOCAINE_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "RAFATHRICIN WITH BENZOCAINE CD",
        "rr": 1.06,
        "risk_count": 42735,
        "predisposition_and_risk": 36,
        "risk_duration": 24052249,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SELEGILINE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 19262,
        "predisposition_and_risk": 26,
        "risk_duration": 22378671,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.T2D.INSULIN",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 69978,
        "predisposition_and_risk": 444,
        "risk_duration": 4734812,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.THERMOMETER",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.06,
        "risk_count": 53349,
        "predisposition_and_risk": 47,
        "risk_duration": 23016809,
        "predisposition_and_risk_duration": 19136,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.LANTHANUM_CARBONATE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "LANTHANUM CARBONATE",
        "rr": 1.06,
        "risk_count": 25784,
        "predisposition_and_risk": 19,
        "risk_duration": 27409174,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.LYTEERS.2FV.2DTEARS",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "LYTEERS/V-TEARS",
        "rr": 1.06,
        "risk_count": 64668,
        "predisposition_and_risk": 107,
        "risk_duration": 18235762,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ANESTHETIC.2FOTIDIN_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ANESTHETIC/OTIDIN CD",
        "rr": 1.04,
        "risk_count": 39328,
        "predisposition_and_risk": 60,
        "risk_duration": 19444301,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.FUROSEMIDE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "FUROSEMIDE",
        "rr": 1.04,
        "risk_count": 83668,
        "predisposition_and_risk": 435,
        "risk_duration": 5709114,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.IMMUNOGLOBULINS_IV_HUMAN",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "IMMUNOGLOBULINS IV HUMAN",
        "rr": 1.04,
        "risk_count": 20656,
        "predisposition_and_risk": 15,
        "risk_duration": 27387969,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.KALGARON_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "KALGARON CD",
        "rr": 1.04,
        "risk_count": 30165,
        "predisposition_and_risk": 44,
        "risk_duration": 20330186,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.WATER_FOR_INJECTION",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.03,
        "risk_count": 12459,
        "predisposition_and_risk": 16,
        "risk_duration": 22750587,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.DARBEPOETIN_ALFA",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "DARBEPOETIN ALFA",
        "rr": 1.03,
        "risk_count": 91615,
        "predisposition_and_risk": 83,
        "risk_duration": 21844976,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.PHENOBARBITAL",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "PHENOBARBITAL",
        "rr": 1.02,
        "risk_count": 33952,
        "predisposition_and_risk": 26,
        "risk_duration": 25598857,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.SALICYLIC_ACID",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "NA",
        "rr": 1.02,
        "risk_count": 26863,
        "predisposition_and_risk": 37,
        "risk_duration": 21070585,
        "predisposition_and_risk_duration": 28474,
        "type": "NA"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.HYDROGEN_PEROXIDE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "HYDROGEN PEROXIDE",
        "rr": 1.02,
        "risk_count": 41179,
        "predisposition_and_risk": 32,
        "risk_duration": 25067767,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ASCORBIC_ACID.2DROSE_HIPS_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ASCORBIC ACID-ROSE HIPS CD",
        "rr": 1.01,
        "risk_count": 51051,
        "predisposition_and_risk": 41,
        "risk_duration": 24063422,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BACK_BRACE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BACK BRACE",
        "rr": 1.01,
        "risk_count": 32553,
        "predisposition_and_risk": 46,
        "risk_duration": 20331004,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.BALNEUM_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BALNEUM CD",
        "rr": 1.01,
        "risk_count": 11771,
        "predisposition_and_risk": 15,
        "risk_duration": 22638842,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CERUMOL_CD",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "CERUMOL CD",
        "rr": 1.01,
        "risk_count": 12480,
        "predisposition_and_risk": 16,
        "risk_duration": 22366089,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.INSULIN_DEGLUDEC",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "INSULIN DEGLUDEC",
        "rr": 1.01,
        "risk_count": 28032,
        "predisposition_and_risk": 20,
        "risk_duration": 27022640,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.MYCOPHENOLIC_ACID",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "MYCOPHENOLIC ACID",
        "rr": 1.01,
        "risk_count": 46532,
        "predisposition_and_risk": 37,
        "risk_duration": 24207027,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.ROPINIROLE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ROPINIROLE",
        "rr": 1,
        "risk_count": 27470,
        "predisposition_and_risk": 36,
        "risk_duration": 21738687,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.BACLOFEN",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "BACLOFEN",
        "rr": 1,
        "risk_count": 40566,
        "predisposition_and_risk": 31,
        "risk_duration": 25049096,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "male",
        "track": "WZMN.med.CROMOGLICIC_ACID",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "CROMOGLICIC ACID",
        "rr": 1,
        "risk_count": 11059,
        "predisposition_and_risk": 14,
        "risk_duration": 22545595,
        "predisposition_and_risk_duration": 28474,
        "type": "Med"
      },
      {
        "age_group": "[60,70)",
        "gender": "female",
        "track": "WZMN.med.ELASTIC_BANDAGE",
        "predisposition": "cohort.5Fc.5Ff74b9c92bc0517005234279f26646e4a",
        "risk": "ELASTIC BANDAGE",
        "rr": 1,
        "risk_count": 48898,
        "predisposition_and_risk": 38,
        "risk_duration": 24723959,
        "predisposition_and_risk_duration": 19136,
        "type": "Med"
      }
    ],
    "figures": null,
    "messageType": "chronicDiseaseCohorts.report",
    "requestId": "e7dbba2a-c07f-43f1-ad09-d529fc9139d9",
    "cohortId": "c_f74b9c92bc0517005234279f26646e4a"
  },
  "id": "63d190c7-a911-4500-baf0-cf5aab845408"
}